Company Overview and News

12
FTK / Flotek Industries Inc. / Gates Capital Management, Inc. - 13G/A (Passive Investment)

2018-09-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
FTK

12
FTK / Flotek Industries Inc. / Gates Capital Management, Inc. - 13G/A (Passive Investment)

2018-09-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
FTK

14
Flotek Industries Is Making Adjustments For A Solid Recovery

2018-08-31 seekingalpha - 1
Flotek Industries (FTK) provides chemistry and services that are used in the oil and gas industries and in the consumer and industrial markets. In 2018, so far, Flotek Industries' stock price has dipped by 53%, while VanEck Vectors Oil Services ETF (OIH) declined 4%. OIH represents the oilfield equipment & services (or OFS) industry. FTK has some near-term challenges from the operational perspective as well as some structural headwinds.
NOV FTK

153
Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL

12
Are Options Traders Betting on a Big Move in Flotek Industries (FTK) Stock?

2018-08-16 zacks
Investors in Flotek Industries, Inc. (FTK - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $3.00 Put had some of the highest implied volatility of all equity options today.
FTK

12
Flotek Industries, Inc. (FTK) CEO John Chisholm on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good morning, and welcome to the Flotek Industries Incorporated Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. This conference is being recorded.
FTK

12
FTK / Flotek Industries Inc. 8-K (Current Report)

2018-08-08 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FTK

13
Flotek Industries (FTK) Reports Q2 Loss, Lags Revenue Estimates

2018-08-08 zacks
Flotek Industries (FTK - Free Report) just came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.
KRO CIVI SBOW FTK

12
FTK / Flotek Industries Inc. 8-K (Current Report)

2018-07-16 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FTK

14
FTK / Flotek Industries Inc. 11-K

2018-06-27 sec.gov - 11
Document UNITED STATES
FTK

8
FTK / Flotek Industries Inc. S-8

2018-06-25 sec.gov - 5
Document UNITED STATES
FTK

7
FTK / Flotek Industries Inc. 8-K (Current Report)

2018-06-13 sec.gov - 4
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FTK

4
FTK / Flotek Industries Inc. FORM 8-K (Current Report)

2018-06-06 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FTK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to FTK / Flotek Industries Inc. on message board site Silicon Investor.

Lifetech (LFTK) Lifetech (LFTK) Lifetech (LFTK) Softkey (SKEY)? Softkey (SKEY)? Softkey (SKEY)?
EFTK (EFTEK Corp.) EFTK (EFTEK Corp.) EFTK (EFTEK Corp.) SOFTKEY=MERGER MANIA SOFTKEY=MERGER MANIA SOFTKEY=MERGER MANIA
The Learnings Co./Softkey = Merger Mania The Learnings Co./Softkey = Merger Mania The Learnings Co./Softkey = Merger Mania
CUSIP: 343389102